Trial Profile
Phase 1/2 study of peptide vaccination associated with CT-GM-01, a galactomannan oligomer that inhibits galectin-3, in patients with advanced metastatic melanoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 01 Apr 2022
Price :
$35
*
At a glance
- Drugs Galactomannan (Primary) ; MAGE-A3 peptide vaccine; MAGE-A3 peptide vaccine; NA17-A2 peptide vaccine; NA17-A2 peptide vaccine
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 26 Mar 2022 This trial has been completed in Belgium according to European Clinical Trials Database record (Global end date: 1 Mar 2016).
- 15 Jan 2014 Status changed from recruiting to suspended, as reported by a Galectin Therapeutics media release.
- 29 Nov 2012 New source identified and integrated (ClinicalTrials.gov record NCT01723813).